Preliminary grip strength data from an 8‐week pilot trial of creatine monohydrate supplementation in Alzheimer’s disease patients

• DOI: 10.1002/alz.092602
• Publication Date: 2025-01-09T11:46:42Z
• Authors: Aaron N. Smith; Debra K Sullivan; Emma Kelly; Tanu N Arora; Faith N Waitsman; Matthew K Taylor
• Keywords: Creatine Monohydrate; Creatine

Abstract Background Diminished muscle function and strength are linked to an increased risk accelerated progression of Alzheimer’s disease (AD). Although these direct consequences the disease, recent preclinical evidence suggests decreased may directly influence AD via muscle‐brain axis. Therefore, interventions improve prevent functional decline related AD. However, such specific in lacking. In this context, creatine monohydrate (CrM), a dietary supplement that boosts strength, presents promising intervention. This single‐armed pilot study explores potential effects 8‐week supplementation on handgrip Method Data from 16 participants with who completed one‐arm, trial examining feasibility preliminary efficacy 20 g/day CrM were analyzed. Handgrip reliable measure was assessed dominant hand at baseline end calibrated dynamometer, measured kilograms (kg) force. At 8 weeks, 3 measurements taken; highest value selected. We conducted paired t‐test test for change mean strength. Statistical analyses performed using R (v. 4.3.2; Foundation, Vienna, Austria). significance set p < 0.05. Result Participants 56% male age 72.1 ± 6.4 years baseline. The grip body mass index (BMI) 33.6 11.6 kg 25.4 3.6 kg/m 2 , respectively. After weeks supplementation, improved by 2.6 (36.1 12.1 kg, 0.001). BMI did not change. Conclusion study, associated individuals Our data be valuable maintaining or preventing AD‐related improving